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Splanchnic venous thrombosis in JAK2
V617F mutation positive myeloproliferative
neoplasms – long term follow-up of a
regional case series
Graeme Greenfield1* and Mary Frances McMullin2
Abstract
Background: Splanchnic Vein Thrombosis (SVT) is strongly associated with underlying JAK2 V617F positive
myeloproliferative neoplasms (MPN).
Methods: Patients attending the tertiary haematology service in Northern Ireland with SVT and underlying JAK2
V617F MPN were identified by consultant staff. A retrospective audit was undertaken to examine therapeutic
interventions and relevant outcomes. Descriptive statistics were used for qualitative data whilst students t-test
allowed comparison of quantitative data.
Results: We report on the medium to long term follow-up of fourteen patients presenting with SVT on the
basis of JAK2 V617F positive MPN. Females comprised 78.5% of the patients and there was an average age of
47.3 years at time of diagnosis. There was significant morbidity evident at diagnosis with liver transplantation attempted
in all patients with Budd Chiari (n = 3), oesophageal varices present in 57.1%, ascites present in 42.8% and splenomegaly
evident in 71.4%. 42.8% of patients did not exhibit classical phenotypic blood count findings for MPN at time of
diagnosis. Over a median follow-up of 88.5 months (range = 8–211months) recurrence of SVT was only documented in
the setting of interventional liver procedure. Major haemorrhagic complications were recorded in 35.7% of patients and
there was an association with dual anticoagulation and antiplatelet use. Recurrent thrombosis outside of the splanchnic
venous system occurred in 28.5% of patients, predominantly occurring off therapeutic anticoagulation. No deaths were
recorded and one transformation to myelofibrosis was seen during follow-up. Cytoreduction therapies were routinely
used but had a high discontinuation rate due to cytopenias and intolerance.
Conclusion: This analysis highlights the complexities of management of this group of patients over a period of long
follow-up with a focus on the evidence behind therapeutic options.
Background
Splanchnic vein thrombosis (SVT) describes a heteroge-
neous group of disorders involving venous thrombus
within the portal vein (PVT), superior mesenteric vein,
splenic vein or hepatic veins (Budd-Chiari Syndrome
(BCS)). This life changing diagnosis is associated with sig-
nificant morbidity resulting from liver decompensation.
The Philadelphia chromosome negative myeloproliferative
neoplasms (MPN) likewise compromise a heterogeneous
group of clonal neoplastic disorders characterised by the
overproduction of erythrocytes in polycythaemia vera
(PV), platelets in essential thrombocythaemia (ET) and
bone marrow fibrosis in myelofibrosis (PMF). The JAK2
V617F mutation identified in 95% of PV patients and
around 50% of ET and PMF cases acts as a driver for
clonal proliferation through constitutive activation of the
JAK/STAT pathway [1]. CALR and MPL mutations are
present as driver mutations in the majority of remaining
cases [2, 3].
The presence of a JAK2 V617F mutant clone predis-
poses to the formation of thrombus. This has been doc-
umented in essential thrombocythaemia where JAK2
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V617F positive patients have a higher rate of thrombosis
and in clonal haematopoiesis of indeterminate potential
where the presence of mutated JAK2 is associated with
an increased risk of coronary artery disease [4, 5]. JAK2
V617F positive MPNs have been identified as the most
common underlying cause in splanchnic vein thrombosis
not associated with local factors, for example cirrhosis
or malignancy. In a prospective study of 604 patients
with proven SVT, underlying overt MPN was identified
in 8% of patients whilst the JAK2 V617F mutation was
detected in 20% [6]. In a meta-analysis, it was demon-
strated that 40.9% of SVT and 41.1% of BCS have an
underlying MPN and 41.1% of PVT and 27.7% of BCS
patients have the JAK2 V617F mutation [7]. JAK2 V617F
allele burden is often low in these patients [8]. A small
number of JAK2 V617F negative patients will develop
positivity with follow-up over subsequent months [9].
The number of CALR positive patients detected in the
context of SVT is much lower at around 0–2.5% [10].
There is little published on the medium to long term
outcomes of this specific patient population. This retro-
spective analysis of a case-series of 14 patients present-
ing with SVT on the basis of underlying JAK2 V617F
positive MPN was undertaken to examine these out-
comes and response to real world therapy of this patient
group. It highlights a number of key complexities in the
management.
Methods
Fourteen patients with SVT in the setting of JAK2
V617F positive MPN were identified following attend-
ance at the outpatient haematology service. A retro-
spective audit of therapeutic interventions and outcomes
was undertaken. Electronic care records and patient
notes were reviewed. Statistical analysis was performed
using the Student’s t test for quantitative data. P values
< 0.05 were considered statistically significant.
Results
The relevant demographics of the patient population at
presentation are shown in Table 1. In all cases, SVT was
the presenting feature of MPN. All patients were positive
for the JAK2 V617F mutation as a condition of inclusion
in this case series. Patients with MPN diagnosed prior to
the discovery of the JAK2 V617F mutation have been in-
cluded on the basis of subsequent proof of positivity. Fe-
male patients comprised 78.5% and there was an average
age of 47.3 years at the time of diagnosis across the co-
hort. Previous thrombotic events had been documented
in two patients, these were one cerebral venous throm-
bosis and one placental thrombosis. In the case of the
cerebral venous thrombosis this patient was on anticoa-
gulation at the time of the SVT. No additional inherited
or acquired pro-thrombotic conditions were detected
however screening for these conditions was not univer-
sally performed (50% screened for PNH, 43% for Factor
V Leiden, 71% for antiphospholipid syndrome, 36% for
anti-thrombin deficiency and 29% for protein C or pro-
tein S deficiency). There was a very low incidence of
co-existing cardiovascular risk factors and/or hormonal
therapy use.
Significant morbidity from liver failure were evident at
diagnosis. Portal venous hypertension was common in all
groups of SVT with 42.8% of patients presenting with as-
cites and 57.1% of patients presenting with oesophageal
varices. Splenomegaly was particularly common, evident
in 71.4% of patients and may reflect the potential dual
aetiology of MPN and portal venous hypertension. Liver
interventions were common in the Budd Chiari patient
group with all three patients undergoing attempted trans-
plantation. Of these attempts, one was abandoned during
the procedure and the other two were successful.
Trans-jugular intrahepatic portosystemic shunts (TIPS)
had been used prior to transplant in two of these patients.
There were no invasive liver procedures in the non Budd
Chiari group other than banding of varices. One patient
has developed definite cirrhosis during follow-up con-
firmed on fibroscan, this was the one Budd Chiari patient
who had a failed liver transplant.
In six of the fourteen patients (42.8%), the initial full
blood count was not typical of a classical myeloprolifera-
tive neoplasm and did not meet diagnostic criteria for
classification as PV, ET or PMF. This finding of a high
number of “latent” MPN diagnoses is commonly re-
ported in this group.
Median follow-up was 88.5months (range = 8–211
months) with no deaths recorded during this time. Trans-
formation to secondary myelofibrosis was recorded in one
patient at 118months follow-up. There were no recorded
transformations to acute leukaemia. One patient was lost
to follow-up at 96months due to relocation.
The complexity of management was demonstrated by the
variation in anticoagulation and antiplatelet therapeutic
strategies employed at initial diagnosis through to recent
follow-up. Figure 1 demonstrates the use of anti-thrombotic
strategies in each patient. After diagnosis, the majority of
patients were managed on single agent anticoagulation with
Vitamin K antagonist (VKA) therapy. A smaller number re-
ceived dual therapy with VKA alongside an aspirin. How-
ever, two of these three patients had this strategy
discontinued relatively quickly in the course of follow-up
and only one additional patient was commenced on this ap-
proach following a further thrombotic event. Antiplatelet
only regimes were less frequently used. One patient was
withdrawn from either anti-coagulation or anti-platelets
due to recurrent bleeding. Low molecular weight heparins
were only used on short term basis initially or as bridging
therapy, novel oral anticoagulants were not used.
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Hydroxycarbamide and interferon alpha are the most
common agents used for cytoreduction. Use of these
agents was widespread with 78.5% of patients exposed to
cytoreduction during follow-up. Rates of intolerance and
ineffectiveness of therapy were high with a number of
changes in the therapeutic strategy used evident during
follow-up. Reasons for discontinuation of therapy included
medication side effects, cytopenias, ineffectiveness and
Table 1 Patient Demographics
Budd Chiari Portal Vein Thrombosis Only Portal Vein Thrombosis +/− Splenic Vein +/− Superior
Mesenteric Vein
Number 3 7 4
Sex Male 0 Male 3 Male 0
Female 3 Female 4 Female 4
Age Mean 38.6 Mean 47.5 Mean 53.5
Range 22–49 Range 36–67 Range 38–84
Type of MPN
PV 1 2 2
ET 2 1 0
PMF 0 0 0
Latent/Unclassifiable 0 4 2
Blood Counts
Hb (g/l) Mean 136 Mean 133a Mean 140
Range 127-145 Range 93–200 Range 111–179
White Cell Count (× 109/l) Mean 16.6 Mean 9.4a Mean 11.6
Range 11.7–21.3 Range 5.1–14 Range 8.3–17
Platelets (×109/l) Mean 592 Mean 358a Mean 537
Range 539-656 Range 283–649 Range 369–861
Haematocrit Mean 0.62a Mean 0.40a Mean 0.41
Range 0.39–0.46 Range 0.31–0.57 Range 0.33–0.54
Other Inherited pro-thrombotic condition 0 0 0
On Anticoagulant at time event 1 0 0
On Anti-platelet at time of event 0 0 0
Other cardiovascular risk factors 0 1 0
On OCP/HRT at time of event 1 0 0
Previous Venous Thrombosis 1 1 0
Previous Arterial Thrombosis 0 0 0
Prior features suggestive MPN 1 3 0
Liver Intervention
Initial TIPPS 2 0 0
Liver Transplant 2 0 0
Failed Transplant 1 0 0
Complications
Ascites 3 1 2
Splenomegaly 2 5 3
Varices 0 6 2
Follow-up (months) Mean 114 Mean 116 Mean 50.7
Range 47–211 Range 65–204 Range 8–118
This shows the demographics of the patient population in each subclassification of splanchnic vein thrombosis
aData not available for 1 patient
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clinical trial participation. Figure 2 demonstrates the use
of cytoreduction. Reasons for change of therapy are re-
corded. From point of diagnosis through to most recent
follow-up, the use of cytoreductive therapies across the
cohort resulted in a significant decrease in the total white
cell count with a decrease of 4.4 × 109/l (P = 0.004) and
platelets with a decrease of 219 × 109/l (P = 0.001) and a
non significant reduction in haemoglobin. This is consist-
ent with the known actions of these drugs.
In half of patients, follow-up was complicated by throm-
bosis, bleeding or both. The time points for these events
are demonstrated in Fig. 1. Significant haemorrhagic
Fig. 1 A diagram showing the use of anticoagulation and/or antiplatelet agents in the management of each patient. Each bar shows time of
follow-up each therapy was used from point of initial diagnosis through to most recent follow-up. Episodes of Bleeding (B) are marked with a red
box, Episodes of Arterial (A) and Venous (V) thrombosis are marked with a cream box and transformation to Myelofibrosis (MF) is marked with a
black box. VKA = Vitamin K antagonist, ASA = Aspirin, VKA/ASA = Dual Vitamin K antagonist and Aspirin therapy
Fig. 2 A diagram demonstrating the cytoreductive therapies used in the management of each patient. Each bar shows the time from point of
diagnosis through to most recent follow-up that each therapy was used. Episodes of Cytopenia and Intolerance are recorded. HU =Hydroxycarbamide,
IFN = Interferon, RUX = Ruxolitinib
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events recorded during follow-up were oesophageal vari-
ceal bleeds, haematuria, tongue laceration and sub-dural
haematoma. Recurrent variceal haemorrhage occurred in
one patient. Of the bleeding events recorded, patients
were on dual anticoagulation and antiplatelet therapy in
three cases, antiplatelet therapy only in one case and anti-
coagulant therapy only in one case demonstrating a par-
ticularly high bleeding risk with dual therapy.
Recurrence of SVT only occurred once during an inva-
sive liver procedure (attempted liver transplantation) in
a BCS patient. A TIPS shunt was occluded in one pa-
tient. Outside of the splanchnic venous system, there
was one arterial event (transient ischaemic attack) dur-
ing follow-up and three venous thrombotic events.
These were bilateral pulmonary emboli, cerebral venous
thrombosis and bilateral jugular vein thrombosis. One of
these events occurred on therapeutic anticoagulation,
one on prophylactic low molecular weight heparin and
one on aspirin.
Discussion
Our case series documents the medium to long term
follow-up for patients with SVT and underlying JAK2
V617F positive MPN, highlighting a number of complex-
ities in the management of these patients. Our findings
were in keeping with previously documented observa-
tions that the demographic of this group tends towards
younger, female patients [8]. This contrasts to the
proven high thrombotic risk group within the general
MPN population which is defined by age over 60 years
and previous thrombosis [11]. Unsurprisingly, we noted
significant morbidities at the outset for all groups of
SVT, with liver transplant attempted in all BCS patients.
The presence of the JAK2 V617F clone has been associ-
ated with higher Child-Pugh scores in BCS indicative of
more severe pathology [12].
Current recommendations suggest that the absence of
classical blood count findings in unprovoked SVT should
not preclude JAK2 V617F testing [7]. Our findings
would again emphasize this importance with almost half
of the patients presenting without a classical MPN
phenotype in the full blood count. A number of reasons
have been suggested to account for this including
hypersplenism, haemodilution related to portal hyper-
tension and/or iron deficiency related to blood loss. Ele-
vated red cell masses have been demonstrated in this
cohort despite normal haematocrit [12]. The presence of
JAK2 V617F appears to function as an all or nothing ef-
fect with JAK2 V617F allele burden previously observed
to be low in this patient group [8] The number of re-
ported cases of SVT in the presence of CALR or MPL
mutations are very low [13]. This is in keeping with a
direct role of the presence of the JAK2 V617F mutation
on the propensity to form clot in the splanchnic veins.
There is evidence to suggest increased interaction be-
tween PV erythrocytes and endothelial cells resulting
from increased phosphorylation of glycoproteins medi-
ated directly by abnormal JAK/STAT signalling [14]. The
JAK2 mutation has also been detected in the endothelial
cells of the liver in BCS patients [15], endothelial pro-
genitor cells [16] and splenic endothelial cells [17] there-
fore allowing the hypothesis that abnormal, activated
blood cells interact with abnormal endothelial cells
resulting in a propensity to form clot. Of interest, JAK2
V617F mutations have been identified in individuals with
no MPN phenotype. This “clonal haematopoiesis of in-
determinate potential” or CHIP is associated with a sig-
nificantly elevated risk of coronary artery disease when
the driving mutation is JAK2 [4]. This is again in keeping
with a direct effect of mutated JAK2 on the thrombotic
risk.
The complexity of management is highlighted by the
use of anti-platelet, anticoagulation and cytoreduction in
our cohort. Until recently, the lack of any effective agent
with potential for disease modification has limited the
goal of therapy to the prevention of further thrombotic
events. The use of aspirin as an anti-platelet agent has
been demonstrated to reduce the thrombosis risk in PV
and its use has been extrapolated to high risk ET in clin-
ical practice [18]. Anticoagulants remain the mainstay
for prevention of venous thromboembolism (VTE) in
the general population. We observed a heterogeneous
approach to anti-platelet and anticoagulant use even in a
small regional case series. There is a lack of consensus
amongst haematologists treating MPN-SVT regarding
anticoagulation reported [19], but it is apparent from
our data that individual circumstances also impact on
the therapies that are safe and tolerable. The optimum
therapy for prevention of recurrent SVT and/or further
VTE outside of the splanchnic veins in this setting has
never been derived from a prospective clinical trial.
Combination therapy using both anticoagulant and anti-
platelet agents is consistently regarded as high risk for
bleeding in all settings and this was evident from our ob-
servations. Oesophageal varices were common and des-
pite concurrent management and banding under the
hepatology teams, variceal haemorrhage in particular re-
mains a significant risk. Recurrent thrombosis is also
problematic. Arterial events were uncommon and only
one venous thrombosis occurred on therapeutic anticoa-
gulation during follow-up suggestive that this strategy is
generally effective. The ongoing persistence of the pro-
voking factor favours long term anticoagulation in
current guidelines [20, 21]. Ongoing anticoagulation
with VKA has demonstrated lower rates of thrombosis
in larger series of SVT patients with MPN [22]. In a
large Danish cohort studies of all cause SVT (1915 pa-
tients), higher bleeding rates have been demonstrated
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for up to 10 years in comparison to deep vein throm-
bosis or pulmonary embolus patients and for up to 19
years in comparison to the general population [23]. In
another cohort of 604 all cause SVT patients including
incidentally detected SVT, the rate of major bleeding
was 3.9 events per 100 patient years on anticoagulation
with higher rates of bleeding evident in cirrhotic patients
[6]. A further cohort of 521 patients with a majority of
incidental SVT diagnoses suggested that although the
rates of bleeding and recurrent thrombosis were similar,
the severity of bleeding complication on anticoagulation
was worse [24]. The number of patients with MPN were
low in all of these studies. Our study has highlighted the
use of dual anti-platelet and anticoagulation results in a
high bleeding risk in this specific population. Use of this
strategy should therefore be carefully considered only on
a case specific basis.
Direct oral anticoagulants (DOACs) have largely re-
placed VKA in the practical management of many
thrombotic events over the past 5 years. They were not
used at all in our cohort. Given the small numbers of pa-
tients involved, it is unlikely that a prospective study
comparing the effectiveness of DOACS to traditional
anticoagulation with VKA in the setting of JAK2 V617F
positive SVT will ever occur. One recently published
treatment algorithm has suggested that their use may be
justifiable in this setting [25]. This conclusion was based
on the increasing demonstration of DOAC efficiency in
malignancy settings and one study reporting on effective
use in SVT generally [26, 27]. Individualised choice of
DOACs based on the presence or absence of varices (in-
creased gastrointestinal bleed risk with dabigatran and
rivaroxaban), the extent of liver impairment and the use
of potentially interacting agents may be a therapeutic
strategy more widely employed in the coming years as
familiarity and evidence grows with their use in atypical
thrombosis sites and malignancy more generally. It is in-
teresting to speculate how this might impact particularly
on our group of individuals with both recurrent bleeding
and thrombosis during follow-up.
Cytoreduction strategies have demonstrated efficacy at
clot prevention in high risk patients with PV [28, 29].
During follow-up we observed a significant number of
discontinuations of commonly used cytoreduction ther-
apies including HU and interferon alpha. This was on
the basis of intolerance and cytopenias. As many of
these patients do not present with the classical polycy-
thaemia or thrombocythaemia they are at risk of devel-
oping low counts as they start at a lower baseline than
most MPN patients. Ruxolitinib acts as a direct JAK in-
hibitor and appears to be safe in this patient group [30].
In the RESPONSE studies evaluating ruxolitinib in PV,
there was a reduction in thrombosis in the ruxolitinib
treated arm in comparison to those patients on best
available therapies [31]. Whether direct inhibition of the
JAK/STAT pathway may independently reduce the risk
of thrombosis in this population is a key question given
the high bleeding risk that is evident, particularly in
some individuals within this group. Of course ruxolitinib
is also associated with cytopenias which may limit its
use in this setting.
Conclusion
The management of SVT in the setting of JAK2 V617F
positive MPN is complex. This retrospective analysis is
in keeping with a younger, predominantly female cohort
often with significant morbidity from liver decompensa-
tion at the outset. Bleeding rates were high during
follow-up and associated with dual anticoagulation and
anti-platelet administration. We did not observe recur-
rence of SVT outside of invasive liver intervention.
Thrombosis outside of the splanchnic venous system oc-
curred infrequently on therapeutic anticoagulation but
more frequently when the patient was not on thera-
peutic anticoagulation. Cytoreduction is often poorly tol-
erated due to side effect profile or cytopenias in this
group. Although we did not observe any deaths there is
clearly still an unmet need to improve therapies available
to this group. Understanding if direct JAK/STAT inhib-
ition may independently reduce the risk of thrombosis is
a key future step, particularly in light of the high haem-
orrhage risk evident.
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